DD

Business profile & competitive position

DuPont de Nemours, Inc. is classified under Basic Materials / Chemicals and describes itself as a provider of advanced solutions for healthcare, water, construction and industrial end markets. Following a major restructuring, the company now reports through two segments — Healthcare & Water Technologies and Diversified Industrials — while its Electronics, Aramids and historical M&M businesses are treated as discontinued operations. Continuing operations include medical packaging and devices, water filtration and purification products, building-envelope and interior solutions, and industrial adhesives, lubricants, engineered shapes and printing plates.

The asset base is globally distributed: at December 31, 2025 the company had subsidiaries in about 50 countries, manufacturing in about 20 countries, and roughly 15,000 employees, including about 1,700 tied to the Aramids Business. Intellectual property is sizeable, with about 6,100 patents and patent applications globally, of which about 4,700 relate to continuing operations and more than 70% have a remaining term of more than five years. That patent estate points to a technology-driven business model, but current profitability is weak: net margin is only 0.7% and return on equity is 0.3%. Those figures suggest the remaining moat is not yet translating into strong bottom-line returns for shareholders.

Financial posture

DuPont currently trades with a market capitalization of $17.5 billion and a trailing P/E ratio of 281.7. That multiple sits far above what a typical chemical producer would command, and it is disconnected from the current net margin of 0.7% and ROE of 0.3%. The gap between price and current earnings implies the market is pricing in a sharp earnings recovery, cost reductions, capital returns or a rerating after asset sales rather than rewarding today’s profitability.

The stock’s beta is 1.08, meaning it has moved slightly more than the broad market on average. At $129.57, the shares are below the 50-day exponential moving average of $135.08 and the RSI is 41.2, a neutral-to-soft momentum reading. The combination of a triple-digit P/E and near-zero margins is the central tension in the financial snapshot: valuation appears to be looking past the current income statement.

Strategic priorities & outlook

DuPont’s most recent 10-K filing outlines four operational priorities. The first is to complete the sale of the Aramids business to Arclin, which was expected around the end of the first quarter of 2026 subject to closing conditions and regulatory approvals. The second is to realize the intended benefits of the Electronics Separation, including the intended tax treatment and the contractual allocation of certain liabilities to Qnity. The third is to execute the $2 billion share buyback authorization announced on November 6, 2025. The fourth is to manage the arrangement to share future eligible PFAS costs among DuPont, Corteva and Chemours, including related litigation and remediation exposures.

The filing also notes that in the fourth quarter of 2025 the company realigned into two reportable segments and recast financial statements as if the M&M, Aramids and Electronics separations had occurred on January 1, 2023. That recast reporting is what makes year-over-year comparisons look unusual and why headline EPS can swing sharply. Management is therefore focused on simplifying the portfolio, returning capital and containing legacy environmental liabilities, rather than on expanding capacity or making large acquisitions.

Macro & geopolitical exposure

As a chemical company, DuPont is exposed to feedstock and energy input costs, regulatory changes affecting chemical manufacturing, and global trade flows. Basic-materials producers typically face margin pressure when oil and natural-gas derivatives rise, and benefit from lower energy prices. Currency movements also matter: roughly 50 countries host subsidiaries, so a stronger U.S. dollar can reduce the dollar value of overseas revenue and earnings.

Beyond cyclical costs, the chemicals sector is heavily exposed to environmental and product-safety regulation. PFAS-related litigation and remediation are industry-wide themes, and DuPont’s cost-sharing agreement with Corteva and Chemours explicitly ties the company to future eligible PFAS liabilities. Healthcare and water end markets add exposure to infrastructure spending and healthcare regulation, while construction-linked products move with building activity and interest rates. Trade policy, including tariffs and export controls, can affect both raw-material sourcing and end-market demand.

Recent developments

The most recent news cluster, dated September 17–19, 2026, has been dominated by institutional position changes and one analytical hold call. On September 19, 2026, Defense World reported that Squarepoint Ops LLC lowered its holdings in DuPont, while also noting that Integrated Wealth Concepts LLC sold 13,713 shares. On September 17, 2026, Zacks published a note titled “Here’s Why You Should Hold DuPont Stock in Your Portfolio for Now,” and Defense World reported that Corient Private Wealth LP sold shares. The sequence suggests at least some institutional distribution around current levels, even as the stock’s analytical coverage leans neutral.

Earnings behavior & post-earnings drift

DuPont has an unusually strong earnings record over the last eight reported quarters, beating the published consensus 8 out of 8 times (100%) and posting an average earnings surprise of 171.1%. The average 5-day price move after those reports is +2.83%, classified as an upward post-earnings drift. The pattern is not just a historical curiosity; the most recent reports confirm it.

On August 4, 2026, DuPont reported actual EPS of $1.88 versus an estimate of $1.76 (6.8% surprise), and the stock rose 3.11% the next day and 1.09% over the following five sessions. On May 5, 2026, actual EPS was $1.65 versus an estimate of $0.4881 (238% surprise), producing a 1.69% next-day move and a 2.64% five-day move. On February 10, 2026, actual EPS came in at $1.38 versus $1.29 (7% surprise), with the stock up 4.25% the next day and 3.88% over the next five days. The prior report on November 6, 2025, showed actual EPS of $3.27 versus an estimate of $0.4656 (602.3% surprise), yet the next-day move was a relatively modest 1.66% and the five-day drift was 3.70%.

The contrast between triple-digit percentage surprises and single-digit stock reactions suggests that the market’s real expectation, or unofficial consensus, may have been well above the published estimate. The next report is scheduled for November 5, 2026 before the open, with a published consensus EPS estimate of $1.87. The historical drift is upward, but the magnitude of the published beat has not reliably predicted the size of the price response.

For a deeper dive into how institutional analysts are modeling DuPont’s earnings, margin recovery and capital-return program, explore the full institutional verdict rather than relying on headline numbers alone.